BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9711054)

  • 1. [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].
    Stichtenoth DO; Zeidler H; Frölich JC
    Med Klin (Munich); 1998 Jul; 93(7):407-15. PubMed ID: 9711054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
    Blain H; Jouzeau JY; Netter P; Jeandel C
    Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology].
    Devillier P
    Presse Med; 2001 Dec 22-29; 30(39-40 Pt 2):70-9. PubMed ID: 11819916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The second generation of COX-2 inhibitors: what advantages do the newest offer?
    Stichtenoth DO; Frölich JC
    Drugs; 2003; 63(1):33-45. PubMed ID: 12487621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
    Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meloxicam: selective COX-2 inhibition in clinical practice.
    Furst DE
    Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New directions in cyclooxygenase research and their implications for NSAID-gastropathy.
    Flower RJ
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():23-7. PubMed ID: 9032578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology].
    Ledro Cano D; Gómez Rodríguez BJ; Torres Domínguez Y; Hergueta Delgado P; Herrerías Esteban JM; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 1999 Apr; 91(4):305-9. PubMed ID: 10348929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
    Peura DA
    Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective cyclooxygenase-2 inhibitors: similarities and differences.
    Brune K; Hinz B
    Scand J Rheumatol; 2004; 33(1):1-6. PubMed ID: 15124935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific rationale for specific inhibition of COX-2.
    Bolten WW
    J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.